# Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation

> **NCT02942576** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company** · enrollment: 632 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Edoxaban
- **DRUG:** VKA-Based Regimen
- **DRUG:** VKA-Based Regimen
- **DRUG:** VKA-Based Regimen
- **DRUG:** VKA-Based Regimen

## Key facts

- **NCT ID:** NCT02942576
- **Lead sponsor:** Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2018-09-24
- **Final completion:** 2018-09-24
- **Target enrollment:** 632 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942576, "Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02942576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*